Foley Hoag Represents ORIG3N in Funding Round

February 9, 2015

Foley Hoag LLP represented ORIG3N, Inc., a leader in regenerative medicine and provider of pluripotent stem cell storage, in its recent round of financing in the amount of $3.1 million. Funding came from an investor syndicate that included Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.

Based in Boston, ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver and neurodegenerative indications. The funding will support the creation of the world's largest bank of pluripotent stem cells to better understand rare genetic inherited diseases and neurodegenerative diseases such as Parkinson's, Alzheimer's, MS and ALS and develop improved treatments.

The Foley Hoag team representing ORIG3N consisted of attorneys Jeffrey Quillen, Colin Zick, Michael Robbat and Patrick Connolly.

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and investment management fields, and in cross-border disputes. Our professionals  possess the skills  and experience to provide exceptional senior level service to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.